Decoy Therapeutics announces special shareholder meeting via webcast

Decoy Therapeutics will hold a virtual special stockholder meeting on Sept. 14, 2026.

Stockholders will vote on allowing the exercise of Series A, Series B and Series C common warrants from a June 2026 private placement. The proposal would permit issuance of up to 2,961,085 common shares upon warrant exercise, potentially generating up to about $17.5 million in gross proceeds.

Stockholders will also vote on reducing authorized common shares to 90,000,000 from 100,000,000.

The meeting includes a proposal to adjourn, if needed, to seek additional proxy support.